Cellibre Inc , a leading cellular agriculture company that employs an organism-agnostic approach to turn cells into specialized sustainable factories for the manufacture of globally significant products at scale today announced the close of an oversubscribed financing round Key investors in this round include Cresco Capital Partners II LLC Flatiron Venture Partners and Delta Emerald Ventures
Biology is the world’s most sophisticated and impactful manufacturing technology Every cell is a manufacturing system equipped with enzymatic machinery instructed by a cell’s DNA code to turn nutrients into products Nature’s machinery can precisely conduct complex reactions that are difficult and in some cases impossible to achieve by any other means By harnessing this innate power of the natural world Cellibre is enabling a revolution in sustainable manufacturing
Cellibre’s initial strategic focus will be deploying its expertise to revolutionize the way cannabinoid-based medicines are sourced produced and consumed The significant deficiencies throughout the current cannabinoid supply chain the resource requirements in the agricultural process and the evolving regulatory environment globally provide Cellibre an immense opportunity to disrupt a + billion market via the production of high-quality sustainable pure medical-grade cannabinoids Cannabinoids represent one of the few industries in the last 50 years to reach 5 billion in sales in the United States and then is expected to post a 20%+ compound annual growth rate for the following five years
We could not be more excited to bring the next industrial revolution bio-based manufacturing to this emerging market said Ben Chiarelli founder and chief executive officer of Cellibre The opportunities for cannabinoid-based products from medicines to cosmetics to animal health and beyond are well known and vast At Cellibre our team is deconstructing the plant into its individual components enabling our innovation partners to scale and commercialize an almost limitless number of products sustainably and consistently ”
Cellibre’s lead investors Cresco Capital Partners Flatiron Venture Partners and Delta Emerald Ventures bring unique perspectives and business expertise to the Cellibre team This group has an expansive network of relationships in the cannabis sector as well as deep industry expertise across the supply chain
Cellibre’s vision to unlock the inherent healing power of the cannabis plant and in partnership with world-class organizations research develop and commercialize cannabinoid-based products aligns perfectly with our mission to play a leading role in bringing this industry out of prohibition to improve human health said Matt Hawkins Founder and Managing Partner of Cresco Capital Partners In this sector like any other we invest in people first The Cellibre team is one of the few scientific groups that has taken bio-based manufacturing from ideation to commercial and has done so by employing very novel and protectable approaches ”
Products derived from cellular agriculture have several significant advantages over legacy manufacturing processes including sustainability consistency purity improved economics and scalability Cannabis is a unique consumer product because while delivering a product with a consistent flavor and aroma is important a consistent experience with these products is equally if not more critical Cellibre’s novel technology will allow brands to deliver on the promise of a consistent experience regardless of geography or scale
About Cellibre
Cellibre is a cellular agriculture company that employs an organism-agnostic approach to turn cells into specialized sustainable factories for the manufacture of globally significant products at scale Our world-class scientific team has led programs from napkin to commercial pioneering revolutionary breakthroughs in energy ingredients medicines and more Cellibre’s initial strategic focus will be deploying our expertise to enable the production of pharmaceutical-grade cannabinoids alleviating the need for agriculture entirely and revolutionizing the way cannabinoid-based medicines are sourced produced and consumed
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Cellibre/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
